Last reviewed · How we verify
Intensive BP control — Competitive Intelligence Brief
marketed
Cardiovascular
Small molecule
Live · refreshed every 30 min
Target snapshot
Intensive BP control (Intensive BP control) — Second Affiliated Hospital of Nanchang University. Intensive blood pressure control reduces cardiovascular and cerebrovascular morbidity and mortality through aggressive pharmacological management of hypertension.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intensive BP control TARGET | Intensive BP control | Second Affiliated Hospital of Nanchang University | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intensive BP control CI watch — RSS
- Intensive BP control CI watch — Atom
- Intensive BP control CI watch — JSON
- Intensive BP control alone — RSS
Cite this brief
Drug Landscape (2026). Intensive BP control — Competitive Intelligence Brief. https://druglandscape.com/ci/intensive-bp-control. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab